NEW YORK (GenomeWeb) – GenomeDx today announced an agreement with Prime Health Services providing coverage of GenomeDx's prostate cancer test.

Under the terms of the deal, the test, called Decipher, will be covered by Prime Health for patients whose physicians order it. Prime Health's network includes 9 million covered lives and brings the total number of covered lives for Decipher to about 120 million, GenomeDx said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.